Is Regeneron Pharmaceuticals Stock Outperforming Its Rivals?
Regeneron‘s stock has underperformed most peers over the past year, reflecting weaker revenue growth, particularly from its Eylea franchise. As of November 16, 2025, how does REGN truly stack up against its biotech rivals? A closer look reveals a moderate valuation and solid profitability, with analysts anticipating moderate upside as new therapies, like Dupixent, gain traction and its diversified pipeline becomes increasingly important in a competitive landscape.
- REGN’s 26.7% operating margin reflects Eylea’s strong profitability, though below GILD’s 38.3% from its robust HIV drug franchise.
- REGN’s 2.9% revenue growth lags peers due to Eylea competition, outpacing GILD whose HIV strength offsets oncology struggles.
- REGN stock, down 8.0% over 1yr, underperforms peers due to Eylea competition and trades at a 15.7 PE, reflecting tempered growth.
Here’s how Regeneron Pharmaceuticals stacks up across size, valuation, and profitability versus key peers.
| REGN | AMGN | GILD | BIIB | BMRN | JAZZ | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 71.8 | 181.2 | 155.4 | 24.6 | 10.5 | 8.6 |
| Revenue ($ Bil) | 14.2 | 36.0 | 29.1 | 10.1 | 3.1 | 4.2 |
| PE Ratio | 15.7 | 25.9 | 19.2 | 15.3 | 20.2 | -23.2 |
| LTM Revenue Growth | 2.9% | 10.6% | 2.8% | 4.8% | 12.4% | 4.1% |
| LTM Operating Margin | 26.7% | 24.1% | 38.3% | 24.8% | 19.9% | 10.9% |
| LTM FCF Margin | 27.2% | 32.1% | 31.5% | 22.5% | 26.7% | 29.8% |
| 12M Market Return | -8.0% | 22.7% | 45.6% | 4.7% | -13.7% | 16.0% |
For more details on Regeneron Pharmaceuticals, read Buy or Sell REGN Stock. Nevertheless, while a single stock can excite, it rarely sustains. Financial advisors who win long term use disciplined allocation – blending equities, gold, and alternatives through trusted partners like ours.
Revenue Growth Comparison
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
- Comfort Systems USA Stock’s Winning Streak May Not Be Over Yet
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 2.9% | 8.3% | 7.8% | -24.3% |
| AMGN | 10.6% | 18.6% | 7.1% | 1.3% |
| GILD | 2.8% | 6.0% | -0.6% | -0.1% |
| BIIB | 4.8% | -1.6% | -3.3% | -7.4% |
| BMRN | 12.4% | 18.0% | 15.4% | 13.5% |
| JAZZ | 4.1% | 6.1% | 4.8% | 18.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 26.7% | 28.8% | 32.3% | 41.0% |
| AMGN | 24.1% | 21.7% | 28.0% | 36.3% |
| GILD | 38.3% | 36.5% | 32.5% | 40.2% |
| BIIB | 24.8% | 22.9% | 18.6% | 28.5% |
| BMRN | 19.9% | 16.6% | 7.7% | 2.7% |
| JAZZ | 10.9% | 17.9% | 15.6% | 14.0% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| REGN | 15.7 | 17.4 | 23.7 | 17.8 |
| AMGN | 25.9 | 34.2 | 22.9 | 21.6 |
| GILD | 19.2 | 240.0 | 17.8 | 23.5 |
| BIIB | 15.3 | 13.6 | 32.2 | 13.2 |
| BMRN | 20.2 | 29.3 | 108.0 | 135.4 |
| JAZZ | -23.2 | 13.6 | 18.8 | -44.5 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.